Division of Oncology/Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands.
Eur Urol. 2017 Jul;72(1):84-109. doi: 10.1016/j.eururo.2016.12.003. Epub 2017 Jan 24.
There is controversy regarding the therapeutic role of pelvic lymph node dissection (PLND) in patients undergoing radical prostatectomy for prostate cancer (PCa).
To systematically review the relevant literature assessing the relative benefits and harms of PLND for oncological and non-oncological outcomes in patients undergoing radical prostatectomy for PCa.
MEDLINE, MEDLINE In-Process, Embase, and the Cochrane Central Register of Controlled Trials were searched up to December 2015. Comparative studies evaluating no PLND, limited, standard, and (super)-extended PLND that reported oncological and non-oncological outcomes were included. Risk-of-bias and confounding assessments were performed. A narrative synthesis was undertaken.
Overall, 66 studies recruiting a total of 275,269 patients were included (44 full-text articles and 22 conference abstracts). Oncological outcomes were addressed by 29 studies, one of which was a randomized clinical trial (RCT). Non-oncological outcomes were addressed by 43 studies, three of which were RCTs. There were high risks of bias and confounding in most studies. Conflicting results emerged when comparing biochemical and clinical recurrence, while no significant differences were observed among groups for survival. Conversely, the majority of studies showed that the more extensive the PLND, the greater the adverse outcomes in terms of operating time, blood loss, length of stay, and postoperative complications. No significant differences were observed in terms of urinary continence and erectile function recovery.
Although representing the most accurate staging procedure, PLND and its extension are associated with worse intraoperative and perioperative outcomes, whereas a direct therapeutic effect is still not evident from the current literature. The current poor quality of evidence indicates the need for robust and adequately powered clinical trials.
Based on a comprehensive review of the literature, this article summarizes the benefits and harms of removing lymph nodes during surgery to remove the prostate because of PCa. Although the quality of the data from the studies was poor, the review suggests that lymph node removal may not have any direct benefit on cancer outcomes and may instead result in more complications. Nevertheless, the procedure remains justified because it enables accurate assessment of cancer spread.
对于因前列腺癌(PCa)而行根治性前列腺切除术的患者,盆腔淋巴结清扫术(PLND)的治疗作用存在争议。
系统评价评估 PLND 对接受根治性前列腺切除术的 PCa 患者在肿瘤学和非肿瘤学结局方面的相对益处和危害的相关文献。
检索了 MEDLINE、MEDLINE In-Process、Embase 和 Cochrane 对照试验中心注册库,检索时间截至 2015 年 12 月。纳入了评估无 PLND、有限、标准和(超)扩展 PLND 的比较研究,这些研究报告了肿瘤学和非肿瘤学结局。进行了风险偏倚和混杂因素评估,并进行了叙述性综合分析。
总体而言,共纳入了 66 项研究,总计 275269 例患者(44 篇全文文章和 22 篇会议摘要)。29 项研究评估了肿瘤学结局,其中 1 项为随机临床试验(RCT)。43 项研究评估了非肿瘤学结局,其中 3 项为 RCT。大多数研究存在较高的偏倚和混杂风险。比较生化和临床复发时结果相互矛盾,而生存率方面各组之间无显著差异。相反,大多数研究表明 PLND 越广泛,手术时间、失血量、住院时间和术后并发症等术中及围手术期结局越差。在尿控和勃起功能恢复方面无显著差异。
尽管 PLND 及其扩展代表了最准确的分期程序,但与当前文献相比,PLND 及其扩展与术中及围手术期结局较差相关,而直接治疗效果仍不明显。当前证据质量较差表明需要进行强有力和充分有力的临床试验。
基于对文献的全面回顾,本文总结了因前列腺癌而行前列腺切除术时清除淋巴结的益处和危害。尽管研究数据的质量较差,但该综述表明淋巴结清除术可能对癌症结局没有任何直接益处,反而可能导致更多并发症。然而,由于该程序可准确评估癌症的扩散,因此该程序仍然合理。